Paul Shapiro

1.1k total citations
31 papers, 669 citations indexed

About

Paul Shapiro is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Paul Shapiro has authored 31 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Computational Theory and Mathematics. Recurrent topics in Paul Shapiro's work include Melanoma and MAPK Pathways (14 papers), Computational Drug Discovery Methods (7 papers) and Synthesis and biological activity (5 papers). Paul Shapiro is often cited by papers focused on Melanoma and MAPK Pathways (14 papers), Computational Drug Discovery Methods (7 papers) and Synthesis and biological activity (5 papers). Paul Shapiro collaborates with scholars based in United States, Singapore and Czechia. Paul Shapiro's co-authors include Alexander D. MacKerell, Fengming Chen, Steven Fletcher, Shilpa A. Worlikar, Jeremy L. Yap, Eun Kyoung Lee, William T. Regenold, Rahul Deshmukh, Alba T. Macias and Hongbing Wang and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Paul Shapiro

31 papers receiving 654 citations

Peers

Paul Shapiro
Noriko Uchiyama Japan
Begoña Cánovas Spain
Denis McCann United States
Wen‐Hsing Lin Taiwan
Yali Deng China
John Kenneth Morrow United States
Leo Lap-Yan Wong Hong Kong
Tony Eight Lin Taiwan
Long G. Wang United States
Robert A. Galemmo United States
Noriko Uchiyama Japan
Paul Shapiro
Citations per year, relative to Paul Shapiro Paul Shapiro (= 1×) peers Noriko Uchiyama

Countries citing papers authored by Paul Shapiro

Since Specialization
Citations

This map shows the geographic impact of Paul Shapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Shapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Shapiro more than expected).

Fields of papers citing papers by Paul Shapiro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Shapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Shapiro. The network helps show where Paul Shapiro may publish in the future.

Co-authorship network of co-authors of Paul Shapiro

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Shapiro. A scholar is included among the top collaborators of Paul Shapiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Shapiro. Paul Shapiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shapiro, Paul, et al.. (2024). Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases. Advances in pharmacology. 100. 181–207. 4 indexed citations
2.
Hasday, Jeffery D., et al.. (2023). Progress in the development of kinase inhibitors for treating asthma and COPD. Advances in pharmacology. 98. 145–178. 4 indexed citations
3.
Zhang, Yong, Billy Truong, Shawn P. Fahl, et al.. (2022). The ERK2 DBP domain opposes pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm. Blood. 140(4). 359–373. 2 indexed citations
4.
Hasday, Jeffery D., et al.. (2020). Kinase inhibitors in the treatment of obstructive pulmonary diseases. Current Opinion in Pharmacology. 51. 11–18. 15 indexed citations
5.
Kim, Myoung Sook, Ramkishore Gernapudi, Brian M. Polster, et al.. (2020). Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 11(43). 3863–3885. 14 indexed citations
6.
Li, Zhihui, Daochuan Li, Eun Yong Choi, et al.. (2017). Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells. Journal of Biological Chemistry. 292(33). 13890–13901. 45 indexed citations
7.
Apfel, Christian & Paul Shapiro. (2014). Chemosensitivity profile of HCT-116 colorectal cancer cells in 3D spheroids compared to 2D monolayers.. Journal of Clinical Oncology. 32(15_suppl). e14606–e14606. 1 indexed citations
8.
Jung, Kwan‐Young, Ramin Samadani, Jay Chauhan, et al.. (2013). Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Organic & Biomolecular Chemistry. 11(22). 3706–3706. 28 indexed citations
9.
Yang, Hui, et al.. (2013). Metformin Represses Drug-Induced Expression of CYP2B6 by Modulating the Constitutive Androstane Receptor Signaling. Molecular Pharmacology. 85(2). 249–260. 34 indexed citations
10.
Zhang, Jun, Paul Shapiro, & Edwin Pozharski. (2012). Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP. Acta Crystallographica Section F Structural Biology and Crystallization Communications. 68(12). 1434–1439. 15 indexed citations
11.
Deshmukh, Rahul, et al.. (2011). Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9. BMC Cancer. 11(1). 7–7. 37 indexed citations
12.
Shapiro, Paul, et al.. (2010). Use of Inhibitors in the Study of MAP Kinases. Methods in molecular biology. 661. 107–122. 22 indexed citations
13.
Yap, Jeremy L., Shilpa A. Worlikar, Alexander D. MacKerell, Paul Shapiro, & Steven Fletcher. (2010). Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics. ChemMedChem. 6(1). 38–48. 66 indexed citations
14.
Dai, Bojie, X. Frank Zhao, Patrick R. Hagner, et al.. (2009). Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma. Cancer Research. 69(19). 7835–7843. 23 indexed citations
15.
Deshmukh, Rahul, et al.. (2009). Development of Extracellular Signal-Regulated Kinase Inhibitors. Current Topics in Medicinal Chemistry. 9(8). 678–689. 27 indexed citations
16.
Chen, Fengming, Alexander D. MacKerell, Yuan Luo, & Paul Shapiro. (2008). Using Caenorhabditis elegans as a model organism for evaluating extracellular signal-regulated kinase docking domain inhibitors. Journal of Cell Communication and Signaling. 2(3-4). 81–92. 8 indexed citations
17.
Chen, Fengming, et al.. (2006). Activation of extracellular signal‐regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1. Cell Proliferation. 39(4). 261–279. 36 indexed citations
18.
Chen, Fengming, Chad N. Hancock, Alba T. Macias, et al.. (2006). Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorganic & Medicinal Chemistry Letters. 16(24). 6281–6287. 53 indexed citations
19.
Cha, Hyuk‐Jin, et al.. (2005). Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells. Cellular Signalling. 18(1). 93–104. 16 indexed citations
20.
Cha, Hyuk‐Jin, Barbara L. Smith, Kathleen A. Gallo, Carolyn E. Machamer, & Paul Shapiro. (2004). Phosphorylation of golgin-160 by mixed lineage kinase 3. Journal of Cell Science. 117(5). 751–760. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noriko Uchiyama Breakdown of academic impact, for papers by Begoña Cánovas Breakdown of academic impact, for papers by Denis McCann Breakdown of academic impact, for papers by Wen‐Hsing Lin Breakdown of academic impact, for papers by Yali Deng Breakdown of academic impact, for papers by John Kenneth Morrow Breakdown of academic impact, for papers by Leo Lap-Yan Wong Breakdown of academic impact, for papers by Tony Eight Lin Breakdown of academic impact, for papers by Long G. Wang Breakdown of academic impact, for papers by Robert A. Galemmo
Rankless by CCL
2026